Testing a generic version of dasatinib in healthy men
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether a generic version of the drug dasatinib works the same as the original brand-name drug. It is for healthy men only, to see how the body handles the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 50 years old.
- You have been told by a doctor that you are healthy.
- You have not smoked in the last 3 months.
- Your body mass index (BMI) is between 18 and 30.
- You are not taking any medications (including over-the-counter) for at least 15 days before the trial.
- You do not have any chronic health conditions (like heart, kidney, liver, or stomach problems) and have not had stomach surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different medicines for people with chronic myeloid leukemia (CML) whose current treatment with imatinib (Gleevec) has not worked well enough. It tests whether switching to dasatinib (Sprycel) or increasing the dose of imatinib to 600 mg helps get the disease under better control.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
This trial tests a new drug, BL-M24D1, for people with multiple myeloma or other blood cancers that have come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new oral drug (DAT-1604) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if it is safe, how the body processes it, and whether it can shrink or slow tumor growth.
This study tests a new oral medication in healthy men to see how the body absorbs, processes, and eliminates it. It's an early step to determine safety and dosing, and you would be closely monitored.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.